Last reviewed · How we verify

ARCAGY/ GINECO GROUP — Portfolio Competitive Intelligence Brief

ARCAGY/ GINECO GROUP pipeline: 0 marketed, 0 filed, 3 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 3 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
atezolizumab + avastin + platinum-based chemotherapy atezolizumab + avastin + platinum-based chemotherapy phase 3 PD-L1 inhibitor + VEGF inhibitor + platinum-based chemotherapy combination PD-L1, VEGF, DNA (platinum adducts) Oncology
Paraplatin Paraplatin phase 3 Oncology
placebo + avastin + platinum-based chemotherapy placebo + avastin + platinum-based chemotherapy phase 3 Combination therapy: platinum-based chemotherapy + anti-angiogenic monoclonal antibody DNA (platinum agents); VEGF (bevacizumab) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eli Lilly and Company · 1 shared drug class
  2. Guangzhou Institute of Respiratory Disease · 1 shared drug class
  3. Hoffmann-La Roche · 1 shared drug class
  4. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 shared drug class
  5. Liaoning Cancer Hospital & Institute · 1 shared drug class
  6. PPD Development, LP · 1 shared drug class
  7. Peking University Cancer Hospital & Institute · 1 shared drug class
  8. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ARCAGY/ GINECO GROUP:

Cite this brief

Drug Landscape (2026). ARCAGY/ GINECO GROUP — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/arcagy-gineco-group. Accessed 2026-05-16.

Related